Rebirth of the God-level Xueba

Yang Rui had never done a new drug completely, it was too time-consuming and unnecessary.

Few pharmaceutical companies in the world will make a new drug and sell it from beginning to end. For the same reason, a normal pharmaceutical company can't stand the 20-year payback cycle. What kind of a century-old store, a two-hundred-year-old company, if you spend your time on the development of one type of drug, you can only make a few in your life, and you have to prevent about six-sevenths of the chance of failure...

Even the super pharmaceutical companies have their own focus. For example, the most famous Pfizer, their strongest ability is sales. Of course, this is not to say that their manufacturing and R&D capabilities are weak. For example, Sildenafil, the main ingredient of Viagra, was developed by Pfizer's branch.

Historically, it took them almost six or seven years to find a suitable compound with activity, and then five or six years of verification, which perfectly proved that sildenafil is useless in lowering blood pressure...

As for developing it into Viagra, it is not so much luck as it is a fight to the death!

For Pfizer, the failure to develop a new drug is an inevitable situation. In any given year, several new drugs cannot be announced as failures.

However, for a researcher who has devoted himself to this, how many decades will he have in his life?

For the researcher in charge of the project, the investment cost is even higher. He has to accumulate experience for at least ten years. It may take fifteen to twenty years before he has the opportunity to host such a project. Counting the previous academic investment, and failing a new drug, especially the first new drug in my life, the result will be disastrous.

Being the person in charge of a laboratory is like being a film director.

Investors allow you to fail. Short-term losses, or even long-term slight losses, can be tolerated. Just like investing 10 million in a movie, 10 million at the box office is not completely unacceptable. Although the director who made this kind of film will not be sought after or even welcome, he can still find a job.

However, if it is a new drug research and development with an investment of 30 million US dollars, the "box office" score obtained is zero, what do investors think?

Can the researcher in charge of this project find any new projects?

Of course, there are still relatively few cases of complete losses in the development of new drugs.

Especially looking at the time span a little bit, the development of new compounds is the lowest risk-relative to the entire new drug development process.

It is also because of this that Yang Rui always started with compounds when he first started.

It has the lowest requirements for laboratories and the smallest requirements for researchers. The most important thing is that as long as the cost is controlled, no matter how bad the compound is, it can be sold for money.

In other words, there are no rotten compounds, only medical experts who can't find a use. For example, Mevastatin was first found by the Japanese Endo Akira. The Sankyo Medical Team led by Akira Endo took more than two years to screen more than 6000 different microorganisms to find the compound, and then it took another seven years to complete the clinical trial.

However, the Japanese stopped clinical trials around 80 years ago, and Gein did animal experiments in dogs, and there was a disturbing increase in the proportion of malignant tumors.

Merck Pharmaceuticals, which screened out similar compounds in 1978, originally wanted to pick a cheap one. This happened to the compound just after spending a lot of money to make it. In order not to let the previous investment go to waste, I had to worry about it. Uneasy continued clinical trials, and finally luckily success, opened the way to sell the tens of billions of blockbuster lovastatin.

Therefore, although the opportunity for the compound to deceive people is great, it can still be sold for money.

Buying and selling compounds is also a very common thing in the pharmaceutical industry.

Yang Rui’s deferiprone compound, a milestone in selling, has now earned hundreds of millions of dollars. Although the new medicine for Gaucher's disease was handed over to Northern Pharmaceutical, it was also a good start for Yang Rui that only foreign companies such as Zelikang were willing to take the money to participate.

Sildenafil's compounds were not expensive nor cheap before 1992.

Pfizer still has expectations for it: a drug that lowers blood pressure, if it works well, it is a proper blockbuster. With 1 billion U.S. dollars in sales each year, the profits must be at least several hundred million U.S. dollars.

It is also for this expectation that Pfizer can endure tens of millions of dollars in expenses each year.

However, when sildenafil was proved to be clinically ineffective around 92 years ago, its value plummeted.

However, Yang Rui was not qualified to check time.

Even useless compounds can become expensive when they fall into Pfizer's hands. This is well known in the market.

If it was dragged around and they found something strange, Yang Rui wouldn't be able to stop it.

Therefore, Yang Rui made a decision and sent two employees from Huarui to contact Pfizer.

At the same time, Yang Rui also let out the wind, saying that Huarui is ready to further develop its pharmaceutical R&D capabilities...

Comrade Li Zhangzhen of Huarui Company was very happy about this.

As the person in charge of the company, the larger the company and the more projects, the stronger the sense of accomplishment.

Compared with just doing medical sales work, the integration of production, education and research sounds much more handsome.

Comrade Li Zhangzhen’s happiness lasted about a week.

In an instant, his excitement disappeared from his eyes, and when he met Yang Rui, his face was even more frustrated: "Pfizer refused."

"Oh, what's the reason?" Yang Rui is not surprised ~ www.wuxiaspot.com~ there is no useful reason, they still don't want to sell sildenafil. "With regret in Li Zhangzhen's words, he asked again: "Do you have any other goals?" "

"Pfizer refused so directly?" Yang Rui cared more about Li Zhangzhen's attitude, he obviously gave up completely.

Li Zhangzhen nodded helplessly, and said: "Pfizer said that since it is the compound that Nobel Laureate Yang Rui is optimistic about, they will at least invest more in trying."

"Uh..." Yang Rui had thought of this possibility, but it was still a bit embarrassing to be told directly by others.

"Mainly because the safety test of sildenafil is very good, Pfizer still has some illusions about it." Li Zhangzhen sighed.

Yang Rui said disapprovingly: "Antihypertensive drugs are commonly used drugs and patients have to take them every day. There is a lot of competition in the market, and the safety is not good, and there is no development value at all."

"But it's not easy to find compounds with good safety." Li Zhangzhen said regretfully: "Pfizer didn't raise the price, so it should be completely uninterested."

"En..." Yang Rui groaned slightly.

"Actually, I learned that there are many good antihypertensive compounds on the market. If you buy them from a small company, it might be easier..."

"Since it's not a question of price, then look for a breakthrough from another angle." Yang Rui didn't take Li Zhangzhen's stubbornness at all, and said to himself: "You ask them to consult Pfizer, just say... the market changes technology. Right."

"Market? What market?" Li Zhangzhen still didn't wake up a bit.

"Of course it is the Chinese market." Yang Rui took the attitude of a GMP committee leader, and said: "You just tell them that if they don't want to talk to us, in the future, if Pfizer's new drugs want to enter the Chinese market, there is no need to talk about it. ."

There should be BGM here!

...